Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity

Future Oncology

Volumn 6, Issue 5, 2010, Pages 837-850

  Al Swiahb, Jamil N ^a   Chen, Chang Han ^a,b   Chuang, Hui Ching ^a   Fang, Fu Min ^a   Tasi, Hsin Ting ^a   Chien, Chih Yen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Array comparative genomic hybridization; Carcinogenesis; Metastasis; MiRNA; Oral cancer n prognosis; Tumor suppressor

Indexed keywords

BETA 2 MICROGLOBULIN; CETUXIMAB; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; GEFITINIB; GELATINASE A; GELATINASE B; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; K RAS PROTEIN; MATRILYSIN; MATRIX METALLOPROTEINASE; MELANOMA ANTIGEN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN;

ALCOHOL CONSUMPTION; BETEL NUT; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CERVICAL LYMPH NODE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 18Q; CHROMOSOME 21Q; CHROMOSOME 3P; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 9P; CHROMOSOME DELETION; CIGARETTE SMOKING; CLINICAL FEATURE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MOUTH CANCER; MOUTH CARCINOMA; NECK DISSECTION; NONHUMAN; ORAL SURGERY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOUTHEAST ASIA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; HUMANS; MOUTH NEOPLASMS;

EID: 77952473366     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.35     Document Type: Review

References (146)

1. Shah JP, Singh B: Keynote comment: why the lack of progress for oral cancer? Lancet Oncol. 7 (5), 356-357 (2006).
2. Rodriguez T, Altieri A, Chatenoud L et al.: Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol. 40 (2), 207-213 (2004).
3. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC: Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J. Oral. Pathol. Med. 24 (10), 450-453 (1995).
4. Ha PK, Califano JA: The role of human papillomavirus in oral carcinogenesis. Crit. Rev. Oral Biol. Med. 15 (4), 188-196 (2004).
5. Garavello W, Bertuccio P, Levi F et al.: The oral cancer epidemic in central and eastern Europe. Int. J. Cancer (2009) (Epub ahead of print).
6. de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP: Oral cavity cancer in developed and in developing countries: populationbased incidence. Head Neck 32 (3), 357-367 (2010).
7. Chien CY, Su CY, Chuang HC et al.: Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol. 45 (9), 798-802 (2009).
8. Schantz SP, Yu GP: Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch. Otolaryngol. Head Neck Surg. 128 (3), 268-274 (2002).
9. Myers JN, Elkins T, Roberts D, Byers RM: Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol. Head Neck Surg. 122 (1), 44-51 (2000).
10. Ghoshal S, Mallick I, Panda N, Sharma SC: Carcinoma of the buccal mucosa: analysis of clinical presentation, outcome and prognostic factors. Oral Oncol. 42 (5), 533-539 (2006).
11. Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ: Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck (2009) (Epub ahead of print).
12. Liao C T, Wang HM, Hsieh LL et al.: Higher distant failure in young age tongue cancer patients. Oral Oncol. 42 (7), 718-725 (2006).
13. Vargas H, Pitman K T, Johnson JT, Galati LT: More aggressive behavior of squamous cell carcinoma of the anterior tongue in young women. Laryngoscope 110 (10 Pt 1), 1623-1626 (2000).
14. Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED: Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol. 35 (3), 257-265 (1999).
15. Liao CT, Ng SH, Chang JT et al.: T4b oral cavity cancer below the mandibular notch is resectable with a favorable outcome. Oral Oncol. 43 (6), 570-579 (2007).
16. Huang SF, Kang CJ, Lin CY et al.: Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer 112 (5), 1066-1075 (2008).
17. Pitman KT, Johnson JT, Myers EN: Effectiveness of selective neck dissection for management of the clinically negative neck. Arch. Otolaryngol. Head Neck Surg. 123 (9), 917-922 (1997).
18. Shah JP, Cendon RA, Farr HW, Strong EW: Carcinoma of the oral cavity. Factors affecting treatment failure at the primary site and neck. Am. J. Surg. 132 (4), 504-507 (1976).
19. Kalnins IK, Leonard AG, Sako K, Razack MS, Shedd DP: Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am. J. Surg. 134 (4), 450-454 (1977).
20. Kokemueller H, Brachvogel P, Eckardt A, Hausamen JE: Neck dissection in oral cancer - clinical review and analysis of prognostic factors. Int. J. Oral Maxillofac. Surg. 31 (6), 608-614 (2002).
21. Shaw RJ, Lowe D, Woolgar JA et al.: Extracapsular spread in oral squamous cell carcinoma. Head Neck (2009) (Epub ahead of print).
22. Sano D, Myers JN: Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 26 (3-4), 645-662 (2007).
23. Liao CT, Wang HM, Chang JT et al.: Analysis of risk factors for distant metastases in squamous cell carcinoma of the oral cavity. Cancer 110 (7), 1501-1508 (2007).
24. Kowalski LP, Bagietto R, Lara JR, Santos RL, Silva JF Jr, Magrin J: Prognostic signifcance of the distribution of neck node metastasis from oral carcinoma. Head Neck 22 (3), 207-214 (2000).
25. Gil Z, Carlson DL, Boyle JO et al.: Lymph node density is a signifcant predictor of outcome in patients with oral cancer. Cancer 115 (24), 5700-5710 (2009).
26. Shrime MG, Ma C, Gullane PJ et al.: Impact of nodal ratio on survival in squamous cell carcinoma of the oral cavity. Head Neck 31 (9), 1129-1136 (2009). • Both nodal ratio and the phenomenon of extracapsular spread of lymph node are independent prognostic factors in disease-specifc survival of oral cancer.
27. Shrime MG, Bachar G, Lea J et al.: Nodal ratio as an independent predictor of survival in squamous cell carcinoma of the oral cavity. Head Neck 31 (11), 1482-1488 (2009).
28. Shaha AR, Spiro RH, Shah JP, Strong EW: Squamous carcinoma of the foor of the mouth. Am. J. Surg. 148 (4), 455-459 (1984).
29. Maddox WA: Hayes Martin lecture. Vicissitudes of head and neck cancer. Am. J. Surg. 148 (4), 428-432 (1984).
30. Asakage T, Yokose T, Mukai K et al.: Tumor thickness predicts cervical metastasis in patients with stage I/II carcinoma of the tongue. Cancer 82 (8), 1443-1448 (1998).
31. Chuang HC, Su CY, Huang HY, Chien CY, Chen CM, Huang CC: High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 116 (7), 1175-1179 (2006). • Higher expression of either CD105 or VEGF in the tumor bed indicates a more aggressive potential for T1 and T2 tongue cancers, and the expression of CD105 is a useful predictive prognostic factor in early tongue cancer.
32. Huang SH, Hwang D, Lockwood G, Goldstein DP, O'Sullivan B: Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer 115 (7), 1489-1497 (2009).
33. Po Wing Yuen A, Lam KY, Lam LK et al: Prognostic factors of clinically stage I and II oral tongue carcinoma - a comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck 24 (6), 513-520 (2002).
34. Bier-Laning CM, Durazo-Arvizu R, Muzaffar K, Petruzzelli GJ: Primary tumor thickness as a risk factor for contralateral cervical metastases in T1/T2 oral tongue squamous cell carcinoma. Laryngoscope 119 (5), 883-888 (2009).
35. Liao CT, Chang JT, Wang HM et al.: Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann. Surg. Oncol. 15 (3), 915-922 (2008).
36. Woolgar JA, Scott J: Prediction of cervical lymph node metastasis in squamous cell carcinoma of the tongue/foor of mouth. Head Neck 17 (6), 463-472 (1995).
37. Odell EW, Jani P, Sherriff M et al.: The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. The importance of the pattern of invasion. Cancer 74 (3), 789-794 (1994).
38. Okamoto M, Ozeki S, Watanabe T, Iida Y, Tashiro H: Cervical lymph node metastasis in carcinoma of the tongue. Correlation between clinical and histopathological fndings and metastasis. J. Craniomaxillofac. Surg. 16 (1), 31-34 (1988).
39. Sawair FA, Irwin CR, Gordon DJ, Leonard AG, Stephenson M, Napier SS: Invasive front grading: reliability and usefulness in the management of oral squamous cell carcinoma. J. Oral. Pathol. Med. 32 (1), 1-9 (2003).
40. Yang TL, Ko JY, Chang YL: Involved margin of tongue cancer: the impact of tumor satellites on prognosis. Head Neck 30 (7), 845-851 (2008).
41. Sugarbaker EV: Cancer metastasis: a product of tumor-host interactions. Curr. Probl. Cancer 3 (7), 1-59 (1979).
42. Close LG, Burns DK, Reisch J, Schaefer SD: Microvascular invasion in cancer of the oral cavity and oropharynx. Arch. Otolaryngol. Head Neck Surg. 113 (11), 1191-1195 (1987).
43. Fagan JJ, Collins B, Barnes L, D'Amico F, Myers EN, Johnson JT: Perineural invasion in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 124 (6), 637-640 (1998).
44. Rahima B, Shingaki S, Nagata M, Saito C: Prognostic signifcance of perineural invasion in oral and oropharyngeal carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 97 (4), 423-431 (2004).
45. Goodman M, Liu L, Ward K et al.: Invasion characteristics of oral tongue cancer: frequency of reporting and effect on survival in a population-based study. Cancer 115 (17), 4010-4020 (2009).
46. Chen Y W, Yu EH, Wu TH, Lo WL, Li WY, Kao SY: Histopathological factors affecting nodal metastasis in tongue cancer: analysis of 94 patients in Taiwan. Int. J. Oral Maxillofac. Surg. 37 (10), 912-916 (2008).
47. D'Cruz AK, Siddachari RC, Walvekar RR et al.: Elective neck dissection for the management of the N0 neck in early cancer of the oral tongue: need for a randomized controlled trial. Head Neck 31 (5), 618-624 (2009).
48. Pandey M, Bindu R, Soumithran CS: Results of primary versus salvage surgery in carcinoma of the buccal mucosa. Eur. J. Surg. Oncol. 35 (4), 362-367 (2009).
49. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning J W, Villaret DB: Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck 26 (11), 984-994 (2004).
50. Liao C T, Chang JT, Wang HM et al.: Does adjuvant radiation therapy improve outcomes in pT1-3N0 oral cavity cancer with tumor-free margins and perineural invasion? Int. J. Radiat. Oncol. Biol. Phys. 71 (2), 371-376 (2008).
51. Bernier J: Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck. Hematol. Oncol. Clin. North Am. 22 (6), 1193-1208, ix (2008).
52. Lilling G, Elena N, Sidi Y, Bakhanashvili M: p53-associated 3'>5' exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 22 (2), 233-245 (2003).
53. Hamakawa H, Nakashiro K, Sumida T et al.: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 30 (6), 800-809 (2008).
54. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61 (5), 759-767 (1990).
55. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG: Advances in the biology of oral cancer. Oral Oncol. 43 (6), 523-534 (2007).
56. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100 (1), 57-70 (2000).
57. Brinkman BM, Wong DT: Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr. Opin. Oncol. 18 (3), 228-233 (2006). • Discusses ongoing research to identify biomarkers for oral cancer.
58. Nagpal JK, Das BR: Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol. 39 (3), 213-221 (2003).
59. Sidransky D: Molecular genetics of head and neck cancer. Curr. Opin. Oncol. 7 (3), 229-233 (1995).
60. Califano J, van der Riet P, Westra W et al.: Genetic progression model for head and neck cancer: implications for feld cancerization. Cancer Res. 56 (11), 2488-2492 (1996).
61. Kupferman ME, Myers JN: Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol. Clin. North Am. 39 (2), 229-247 (2006). • Describes the current knowledge of molecular processes that underlie tumorigenesis in squamous cell carcinoma of the oral cavity.
62. ARF) in patients with severe oral epithelial dysplasia. Cancer Res. 62 (18), 5295-5300 (2002).
63. Choi S, Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 87 (1), 14-32 (2008). bull; Focuses on the molecular mechanisms of oral carcinogenesis and the use of biologic therapy to specifcally target molecules altered in squamous cell carcinoma of the oral cavity.
64. Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol. Pathol. 53 (4), 165-172 (2000).
65. Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53 (15), 3579-3584 (1993).
66. Huang SF, Chuang WY, Chen IH, Liao CT, Wang HM, Hsieh LL: EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. Head Neck 31 (8), 1068-1077 (2009).
67. Hynes NE, Lane HA: ErbB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (5), 341-354 (2005).
68. Shiraki M, Odajima T, Ikeda T et al.: Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod. Pathol. 18 (11), 1482-1489 (2005).
69. Chen IH, Chang JT, Liao CT, Wang HM, Hsieh LL, Cheng AJ: Prognostic signifcance of EGFR and HER-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br. J. Cancer 89 (4), 681-686 (2003).
70. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA: Biological signifcance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 24 (1), 47-69 (2005).
71. Grandis JR, Drenning SD, Zeng Q et al.: Constitutive activation of STAT3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci. USA 97 (8), 4227-4232 (2000).
72. Reuter CW, Morgan MA, Eckardt A: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br. J. Cancer 96 (3), 408-416 (2007).
73. Rittling SR, Chambers AF: Role of osteopontin in tumour progression. Br. J. Cancer 90 (10), 1877-1881 (2004).
74. Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16 (2), 79-87 (2006).
75. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2), 61-85 (2001).
76. Haqq C, Nosrati M, Sudilovsky D et al.: The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102 (17), 6092-6097 (2005).
77. Wai PY, Kuo PC: The role of osteopontin in tumor metastasis. J. Surg. Res. 121 (2), 228-241 (2004).
78. Todd R, Donoff RB, Wong DT: The molecular biology of oral carcinogenesis: toward a tumor progression model. J. Oral Maxillofac. Surg. 55 (6), 613-623;
79. Discussion 623-615 (1997).
80. Milasin J, Pujic N, Dedovic N, Nikolic Z, Petrovic V, Dimitrijevic B: High incidence of H-RAS oncogene mutations in squamous cell carcinoma of lip vermilion. J. Oral. Pathol. Med. 3 7), 98-301 1994).
81. Kuo MY, Jeng JH, Chiang CP, Hahn LJ: Mutations of KI-RAS oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J. Oral. Pathol. Med. 23 (2), 70-74 (1994).
82. Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2 (10), 740-749 (2002).
83. Darnell JE Jr, Kerr IM, Stark GR: ak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (5164), 1415-1421 (1994).
84. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (21), 2468-2473 (2000).
85. Siavash H, Nikitakis NG, Sauk JJ: Signal transducers and activators of transcription: insights into the molecular basis of oral cancer. Crit. Rev. Oral Biol. Med. 15 (5), 298-307 (2004).
86. Masuda M, Suzui M, Yasumatu R et al.: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62 (12), 3351-3355 (2002).
87. Klosek SK, Nakashiro K, Hara S, Li C, Shintani S, Hamakawa H: Constitutive activation of STAT3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma. Oncol. Rep. 12 (2), 293-296 (2004).
88. Lothaire P, de Azambuja E, Dequanter D et al.: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28 (3), 256-269 (2006).
89. Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T: Prognostic signifcance of cyclin D1 amplifcation and overexpression in oral squamous cell carcinomas. Oral Oncol. 39 (6), 610-618 (2003).
90. Rousseau A, Lim MS, Lin Z, Jordan RC: Frequent cyclin D1 gene amplifcation and protein overexpression in oral epithelial dysplasias. Oral Oncol. 37 (3), 268-275 (2001).
91. Yu Z, Weinberger PM, Haffty BG et al.: Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 11 (3), 1160-1166 (2005).
92. Chen HM, Yen-Ping Kuo M, Lin KH, Lin CY, Chiang CP: Expression of cyclin A is related to progression of oral squamous cell carcinoma in Taiwan. Oral Oncol. 39 (5), 476-482 (2003).
93. Chen CH, Su CY, Chien CY et al.: Overexpression of b2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br. J. Cancer 99 (9), 1453-1461 (2008). bull; First report that βoglobulin participated in oral cancer cell migration and invasion.
94. Chen CH, Chien CY, Huang CC et al.: Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 28 (30), 2723-2737 (2009). bull; First report that FLJ10540 could regulate the FOXM1/MMP-2 pathway for modulating the oral cancer cell migration and invasion.
95. Reiter R, Gais P, Jutting U et al.: Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12 (17), 5136-5141 (2006).
96. Chen YJ, Chang JT, Lee L et al.: DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene 26 (3), 467-476 (2007).
97. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T: Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther. 4 (3), 471-476 (2005).
98. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ: Hypoxia-induced tumor angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett. 225 (2), 297-304 (2005).
99. Brener S, Gonzalez-Moles MA, Tostes D et al.: A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res. 29 (6), 2323-2329 (2009).
100. Lo W Y, Tsai MH, Tsai Y et al.: Identifcation of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin. Chim. Acta 376 (1-2), 101-107 (2007).
101. Chang JT, Wang HM, Chang KW et al.: Identifcation of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int. J. Cancer 114 (6), 942-949 (2005).
102. Schliephake H. Rognostic relevance of molecular markers of oral cancer - a review. Int. J. Oral Maxillofac. Surg. 32 (3), 233-245 (2003).
103. Chien CY, Su CY, Chuang HC et al.: Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity. J. Surg. Oncol. 97 (3), 273-277 (2008).
104. Poznic M: Retinoblastoma protein: a central processing unit. J. Biosci. 34 (2), 305-312 (2009).
105. Sartor M, Steingrimsdottir H, Elamin F et al.: Role of p16/MTS1, cyclin D1 and Rb in primary oral cancer and oral cancer cell lines. Br. J. Cancer 80 (1-2), 79-86 (1999).
106. Scambia G, Lovergine S, Masciullo V: Rb family members as predictive and prognostic factors in human cancer. Oncogene 25 (38), 5302-5308 (2006).
107. Massano J, Regateiro FS, Januario G, Ferreira A: Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 102 (1), 67-76 (2006).
108. Baral R, Patnaik S, Das BR: Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Fur. J. Oral Sci. 106 (5), 907-913 (1998).
109. Lyons AJ, Jones J: Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int. J. Oral Maxillofac. Surg. 36 (8), 671-679 (2007).
110. Choi CS, Choi G, Jung KY, Choi JO, Chae YS: Low expression of p27 (Kip1) in advanced mucoepidermoid carcinomas of head and neck. Head Neck 23 (4), 292-297 (2001).
111. Kapranos N, Stathopoulos GP, Manolopoulos L et al.: p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 21 (1B), 521-528 (2001).
112. Mineta H, Miura K, Suzuki I et al.: Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85 (5), 1011-1017 (1999).
113. Fillies T, Woltering M, Brandt B et al.: Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol. Rep. 17 (2), 355-359 (2007).
114. ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107 (1), 81-91 (2009).
115. Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S: Expression of p16 in oral cancer and premalignant lesions. J. Oral. Pathol. Med. 38 (1), 104-108 (2009).
116. Vairaktaris E, Yapijakis C, Psyrri A et al.: Loss of tumour suppressor p16 expression in initial stages of oral oncogenesis. Anticancer Res. 27 (2), 979-984 (2007).
117. Oliveira DT, Sherriff M, Odell EW: Expression of CD44 variant exons by primary and metastatic oral squamous carcinomas. J. Oral. Pathol. Med. 27 (7), 303-307 (1998).
118. Howell GM, Grandis JR: Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck 27 (8), 710-717 (2005).
119. Van Waes C, Carey TE: Overexpression of the A9 antigen/a 6 b 4 integrin in head and neck cancer. Otolaryngol. Clin. North Am. 25 (5), 1117-1139 (1992).
120. Thomas GJ, Speight PM: Cell adhesion molecules and oral cancer. Crit. Rev. Oral Biol. Med. 12 (6), 479-498 (2001).
121. Thomas GJ, Nystrom ML, Marshall JF: αβ6 integrin in wound healing and cancer of the oral cavity. J. Oral. Pathol. Med. 35 (1), 1-10 (2006).
122. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 3 (1), 55-63 (2003).
123. Jezierska A, Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit. 15 (2), RA32-RA40 (2009).
124. Munshi HG, Wu YI, Ariztia EV, Stack MS: Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J. Biol. Chem. 277 (44), 41480-41488 (2002).
125. Chuang HC, Su CY, Huang HY et al.: Active matrix metalloproteinase-7 is associated with invasion in buccal squamous cell carcinoma. Mod. Pathol. 21 (12), 1444-1450 (2008).
126. Werner JA, Rathcke IO, Mandic R: The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin. Exp. Metastasis 19 (4), 275-282 (2002).
127. Hong SD, Hong SP, Lee JI, Lim CY: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 36 (2), 207-213 (2000).
128. Gao ZB, Duan YQ, Zhang L, Chen DW, Ding PT: Expression of matrix metalloproteinase 2 and its tissue inhibitor in oral squamous cell carcinoma. Int. J. Mol. Med. 16 (4), 599-603 (2005).
129. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS: Clinical signifcance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 29 (6), 564-572 (2007).
130. Mertens PR, Harendza S, Pollock AS, Lovett DH: Glomerular mesangial cellspecifc transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J. Biol. Chem. 272 (36), 22905-22912 (1997).
131. Qin H, Sun Y, Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem. 274 (41), 29130-29137 (1999).
132. Bian J, Sun Y: Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17 (11), 6330-6338 (1997).
133. Xie TX, Wei D, Liu M et al.: STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 (20), 3550-3560 (2004).
134. Fox SB, Gasparini G, Harris AL: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2 (5), 278-289 (2001).
135. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG: Prognostic signifcance of vascular endothelial cell growth factors-A, -C and-D in breast cancer and their relationship with angio- and lymphangiogenesis. Br. J. Cancer 96 (7), 1092-1100 (2007).
136. Siriwardena BS, Kudo Y, Ogawa I, Udagama MN, Tilakaratne WM, Takata T: VEGF-C is associated with lymphatic status and invasion in oral cancer. J. Clin. Pathol. 61 (1), 103-108 (2008).
137. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev. Biol. 302 (1), 1-12 (2007).
138. Liu X, Chen Z, Yu J, Xia J, Zhou X: MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics Comp. Funct. Genomics (2009).
139. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6 (4), 259-269 (2006).
140. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat. Rev. Cancer 6 (11), 857-866 (2006).
141. Shinawi M, Cheung SW: The array CGH and its clinical applications. Drug Discov. Today 13 (17-18), 760-770 (2008).
142. Mitelman F, Johansson B, Mertens F: The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7 (4), 233-245 (2007).
143. Sparano A, Quesnelle KM, Kumar MS et al.: Genome-wide profling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope 116 (5), 735-741 (2006).
144. Kallioniemi A: CGH microarrays and cancer. Curr. Opin. Biotechnol. 19 (1), 36-40 (2008).
145. Ries J, Mollaoglu N, Toyoshima T et al.: A novel multiple-marker method for the early diagnosis of oral squamous cell carcinoma. Dis. Markers 27 (2), 75-84 (2009).
146. Nagler RM: Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol. 45 (12), 1006-1010 (2009).